

GFATM status for TB

Dr Pierre-Yves Norval

Ms Andrea Godfrey

WHO Stop TB Department

GFATM support for TB (R1-5)

\$ 1.6 billion life time (18% of all diseases)

\$ 730 M remaining


\$ 51 M pending

\$ 819 M approved

\$ 295 M disbursed
>95% according timing


95 TB grants
72 countries
21/22 HBC

\$ 150 M
spent




Total NTP Budgets by Source of Funding

22 high-burden countries, 2002-2006



TB expenditure in 11 HBC (1/2 world pop, 1/3 TB case world) and impact on S+ CDR



Technical areas in alignment with Stop TB strategy and Global plan

- 👍 DOTS expansion in all R1-5 including lab. support
- 👍 TB/HIV in 63/103 TB and TB/HIV proposals (R1-5)
 - 👍 In 17/25 HIV proposals (R5)
- 👍 MDR represents 75% of MDR projects worldwide
 - 👍 25,000 MDR TB cases (R1-5)
- 👍 ACS in 9/22 (R5)
- 👍 Community TB in 10/22 (R5)
- 👍 PPM in 8/22 HBCs




TA for GFATM at global level

- 🧠 Proposal forms and guidelines
- 🧠 M&E systems
- 🧠 GLC agreement: 2nd line TB drugs procurement and TA
- 🧠 Procurement list of eligible 1st line drugs including GDF
- 🧠 Briefing TRP, portfolio managers

MOU Stop TB Partnership – GF on 19 May 2005

- 👉 **Coordinated TA from Stop TB Partners**
- 👉 **Drug procurement via GDF and GLC**

TA for GFATM at country level



☺ Proposal preparation

☺ TRP clarifications

☺ Grant negotiation - PR

☺ Work plan – PR/SR

☺ M&E plan – PR/SR

☺ Procurement plan - PR/SR/(LFA)


☺ Phase 2 renewal – PR/SR

☺ Regular reporting - PR/SR/(LFA)

☺ EARS response - CCM



TA provided




Qualitative



Quantitative

Coordinated

TA ?



Objectives and expected outcome

-  Needs and challenges of coordination of technical cooperation to implement GFATM grants
-  Proposed next steps for technical assistance on grant preparation, monitoring and phase two renewal